Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: USE Relieves occasional constipation (irregularity) Generally produces a bowel movement in 1 to 3 days US FDA label
Use: Klor-Con is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. US FDA label
Kidney dosing: Potassium chloride (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Hypokalemia treatment: 40 to 100 mEq/day in divided doses, no more than 40 mEq per dose; prevention: about 20 mEq/day. Use IV potassium if serum potassium is below 2.5 mEq/L (label).
- CrCl 30–59 mL/min
- Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). IV concentrate: must be diluted; never IV push (see IV label).
- CrCl 15–29 mL/min
- Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). IV concentrate: must be diluted; never IV push (see IV label).
- CrCl <15 mL/min (not on dialysis)
- Reduced potassium excretion and a much higher risk of hyperkalemia: start at the low end of the dose range, especially with RAAS inhibitors or NSAIDs; monitor serum potassium frequently and kidney function periodically (label 8.7). Specialist input. IV concentrate: must be diluted; never IV push (see IV label).
- Hemodialysis (intermittent)
- No dialysis dose in label; potassium removal depends on the dialysate. Give only for documented hypokalemia, start low and check potassium frequently (label 8.7); specialist input. IV concentrate (2 mEq/mL) must be diluted before use; never give by IV push or undiluted (fatal arrhythmia and cardiac arrest reported). In kidney impairment potassium is retained: use the low end of the infusion rate in the IV product label, with ECG monitoring as needed, and recheck potassium after each replacement. Concentration and rate limits: see the IV product label.
- Peritoneal dialysis
- No PD dose in label. PD patients can become hypokalemic; replace by measured potassium, starting low (label 8.7); specialist input. Hypokalemia is a modifiable risk factor for PD peritonitis (ISPD 2022).
- CRRT
- No data in label; replacement guided by frequent potassium levels and CRRT fluid potassium. Specialist input.
- Dialyzable? Potassium is removed by hemodialysis and peritoneal dialysis (label lists dialysis among hyperkalemia treatments).
- Monitoring Serum potassium frequently in kidney impairment and periodically on maintenance; kidney function; magnesium, acid-base status and ECG in cardiac or kidney disease (label 2.1, 8.7).
From the Potassium chloride monograph (renalcarematters.com, reviewed).
Use: to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. US FDA label
Kidney dosing: Sodium bicarbonate (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- IV for metabolic acidosis (adults and children 2 years and older): 2 to 5 mEq/kg over 4 to 8 hours, by bicarbonate, total CO2, pH and clinical state (label). Treat the cause.
- CrCl 30–59 mL/min
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- CrCl 15–29 mL/min
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- CrCl <15 mL/min (not on dialysis)
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- Hemodialysis (intermittent)
- No dose change; anuria raises the risk of fluid overload from the sodium load (label 5.1). Dialysate bicarbonate also corrects acidosis; coordinate with the dialysis prescription (clinical judgment).
- Peritoneal dialysis
- No dose change; watch sodium load and fluid status (label 5.1).
- CRRT
- No data in label. CRRT fluids are usually bicarbonate-buffered; added IV bicarbonate is a specialist decision guided by blood gases.
- Dialyzable? Bicarbonate crosses dialysis membranes in both directions according to the dialysate bicarbonate concentration (physiology; not stated in label).
- Monitoring Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions).
From the Sodium bicarbonate monograph (renalcarematters.com, reviewed).
Use: INDICATIONS AND USAGE Intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient. US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Powder for oral solution: 13.1 g/350.7 mg/178.5 mg/178.5 mg, 13.12 g/350.7 mg/178.5 mg/46.6 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Polyethylene glycol 3350 + Potassium chloride + Sodium bicarbonate + Sodium chloride as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
HydrilaxePolyethylene glycol 3350 + Sodium Chloride + Sodium bicarbonate +Potassium Chloride | 13.12g/350.7mg/178.5mg/46.6mg powder for oral solutionPolyester film/ Aluminum film/ LDPE Film Printed laminated foil x 14g (Box of 10's) | Rx | BLISS GVS PHARMA LTD.India | Bliss Gvs Pharma Ltd.Importer: BLISS GVS PHARMA LTD. | DR-XY47012 | Aug 12, 2030 | |
NonePolyethylene Glycol 3350 + Sodium Chloride + Sodium Bicarbonate + Potassium Chloride | 13.1 g/350.7 mg/178.5 mg/178.5 mg Powder for Oral SolutionAluminum Foil Sachet x 14 g (Box of 10's) | HR | Lloyd Laboratories, Inc.Philippines | — | DR-XY46686 | Feb 4, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .